Meghann Fior

Learn More
0747-5632/$ see front matter 2008 Elsevier Ltd. A doi:10.1016/j.chb.2008.12.001 q Portions of this paper were presented at the Ann Society for the Study of Education, York University, To * Corresponding author. Tel.: +1 250 721 6347. E-mail address: hadwin@uvic.ca (A.F. Hadwin). This paper addresses the paucity of computer supported collaborative learning(More)
The antiphospholipid antibodies (aPL) present in autoimmune disorders are associated with thromboembolic episodes, and their binding to phospholipids (PL) is mediated by a plasma cofactor, beta 2-glycoprotein I (beta 2GPI). Both PL and beta 2GPI seem necessary for binding, thus indicating that the two components comprise the epitope against which aPL are(More)
Autoimmune antiphospholipid antibodies are a hallmark of patients with antiphospholipid syndrome, and require a protein cofactor, β2-glycoprotein I, to bind anionic phospholipids. In these same patients, moreover, IgG directly binding β2-glycoprotein I are described. We found high plasma titres of both IgM and IgG anti β2-glycoprotein I antibodies in a(More)
4 856 cases of primary lung carcinoma in the Rhônes-Alpes area have been collected from 1970 to 1980 by cytological examination. The validity of these data rests upon the fact that they come from the same laboratory. The percentage of small cell carcinomas has been calculated per year and per geographical area. An increasing incidence is observed starting(More)
Autoimmune CL-rA need a plasma protein, beta 2GPI, to bind anionic PL. While beta 2GPI could be the true antigen, beta 2GPI binding to solid phase heparin did not determine its recognition by CL-rA when using patient plasmas. We tested plasmas from four patients with antiphospholipid syndrome in this study and no CL-rA binding to heparin sepharose was(More)
  • 1